Kliničke studije za Debljina u državi Nevada
29 studija za Debljina traži sudionike na lokacijama u državi Nevada.
Gradovi u državi Nevada
Službeni tekst studije (engleski)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Vector Clinical Trials /ID# 282265, Las Vegas
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT07752979A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Excel Clinical Research, LLC, Las Vegas
- Palm Research Center Tenaya, Las Vegas
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07783802AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Palm Research Center Inc., Las Vegas
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07720271A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Las Vegas
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07776509A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Palm Research Center Tenaya, Las Vegas
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07369011Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Excel Clinical Research, Las Vegas
- Vector Clinical Trials, Las Vegas
U tijeku regrutacijaFaza 3
Od 45 do 99 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- AMR Clinical, Las Vegas
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Las Vegas Medical Research, Las Vegas
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Las Vegas
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Las Vegas
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743450A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Las Vegas
U tijeku regrutacijaFaza 3Zdravi dobrovoljci dobrodošli
Od 18 do 79 godina · Oba spola · Ažurirano 11. ruj 2026. · NCT07654374Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- Jubilee Clinical Research, Inc., Las Vegas
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2026. · NCT07770841A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Las Vegas Medical Research, Las Vegas
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 8. ruj 2026. · NCT06143956A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- Vector Clinical Trials, Las Vegas
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 8. ruj 2026. · NCT07215559A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Skin Cancer and Dermatology Institute - Reno, Reno
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Las Vegas
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Palm Research Center Inc, Las Vegas
- Vector Clinical Trials, Las Vegas
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 3. ruj 2026. · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Las Vegas
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Palm Research Center Inc, Las Vegas
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 3. ruj 2026. · NCT07684144Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Kailera Clinical Site, Las Vegas
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 1. ruj 2026. · NCT07284979Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Excel Clinical Research, Las Vegas
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 27. kol 2026. · NCT07575399Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.
- University of Nevada, Las Vegas, Las Vegas
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 21 do 74 godina · Oba spola · Ažurirano 27. kol 2026. · NCT07566325A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Las Vegas
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT07784725A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- UMC of Southern Nevada, Las Vegas
- Palm Research Center Inc-Vegas, Las Vegas
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 18. kol 2026. · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Las Vegas
U tijeku regrutacijaFaza 3
Od 18 do 79 godina · Oba spola · Ažurirano 10. kol 2026. · NCT07654361A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- Palm Research Center, Mountainview Medical Center, Las Vegas
U tijeku regrutacijaFaza 2
Od 18 do 80 godina · Oba spola · Ažurirano 22. srp 2026. · NCT07477704A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Jubilee Clinical Research, Inc., Las Vegas
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 9. srp 2026. · NCT07481630A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
- Corxel Investigational site, Las Vegas
U tijeku regrutacijaFaza 1
Od 18 do 55 godina · Žene · Ažurirano 17. lip 2026. · NCT07652047Randomized Trial of Healthy Family Foundations
- Nellis Airforce Base, Nellis Air Force Base
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 do 60 godina · Oba spola · Ažurirano 14. tra 2026. · NCT05630482Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.